Bruce Albala

Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project

Karen Ritchie, Michael T. Ropacki, Bruce Albala et al. · Alzheimer s & Dementia · 2016 · 102 citations · Full text

O1‐06‐05: First‐in‐human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta‐amyloid levels after single dosing

Robert Lai, Bruce Albala, June Kaplow et al. · Alzheimer s & Dementia · 2012 · 55 citations

Plasma Beta‐amyloid Levels, Pharmacotherapy, Mg. E2609 +17

Estimated seroprevalence of SARS-CoV-2 antibodies among adults in Orange County, California

Tim A. Bruckner, Daniel M. Parker, Scott M. Bartell et al. · Scientific Reports · 2021 · 50 citations · Full text

Synergistic Effect of an Endothelin Type A Receptor Antagonist, S-0139, With rtPA on the Neuroprotection After Embolic Stroke

Rui Lan Zhang, Chunling Zhang, Li Zhang et al. · Stroke · 2008 · 43 citations · Full text

P4‐389: ELENBECESTAT, E2609, A BACE INHIBITOR: RESULTS FROM A PHASE‐2 STUDY IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT AND MILD‐TO‐MODERATE DEMENTIA DUE TO ALZHEIMER'S DISEASE

Shau Yu Lynch, June Kaplow, Jim Zhao et al. · Alzheimer s & Dementia · 2018 · 34 citations · Full text

Cdr-sb Vs Placebo, Neurochemical Biomarkers, Pharmacotherapy +28